Posted by Michael Wonder on 29 May 2017
Draft report for the post-market review of COPD medicines
29 May 2017 - The draft report for the post-market review of chronic obstructive pulmonary disease medicines is available for public comment.
A Stakeholder Forum was held in Sydney on 21 March 2017. Pharmaceutical sponsors of chronic obstructive pulmonary disease (COPD) medicines listed on the PBS, representatives of peak bodies, consumer organisations, and individuals who provided a submission to the Review were invited to participate.
The draft COPD review report is available below for public comment until 13 June 2017. Some commercial-in-confidence data has been redacted from the draft report.
